Was it worth introducing health economic evaluation of innovative drugs in the French regulatory setting? The case of new hepatitis C drugs

This paper constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research